Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospi talization for respiratory syncytial virus infection. <...> Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. <...> American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. <...> Prevention of respiratory syncytial virus infections: indications for the use of palivizu-mab and update on the use of RSV-IGIV. <...> The Impact-RSV Study Group: Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitali-zation From Respiratory Syncytial Virus Infection in High-risk Infants. <...> Palivizumab Congenital Heart Disease Study: RSV Hospitalization Rates. <...> From the American Academy of Pediatrics: Policy state-ments — Modified recommendations for use ofpalivizumab for prevention of respiratory syncytial virus infections. <...> Respiratory syncytial virus-asso-ciated hospitalizations among children less than 24 months of age. <...> Respiratory syncytial virus associated mortality in hospitalized United States infants and children less than 2 years of age. <...> Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. <...> Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. <...> RSV Immuno prophylaxis: Does the Benefit Justify the Cost? <...> Prais D, Danino D, Schonfeld T, Amir J. Impact of palivizumab on admission to the ICU for respi-ratory syncytial virus bronchiolitis: a national survey. <...> Prospective observational study of PICU hospitalizations due to RSV related bron-chiolitis in 2008–2012. <...> Rates of hospitalization for RSV bronchiolitis for all degrees of prematurity in a single medical Center (Shaare-Zedek). <...> НОВЫЕ СВЕДЕНИЯ О ДОМАШНЕМ ЧТЕНИИ: ВЛИЯНИЕ ОКРУЖАЮЩЕЙ ОБСТАНОВКИ НА АКТИВАЦИЮ СПЕЦИФИЧЕСКИХ ОТДЕЛОВ МОЗГА, ОТВЕЧАЮЩИХ ЗА ВРОЖДЕННУЮ (ПРИРОДНУЮ) ГРАМОТНОСТЬ Джорджио Тамбурлини Центр здоровья ребенка <...>